Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced data from the primary analysis of the Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented this morning as part of the Presidential Symposium at the International Association for the Study of Lung Cancer’s (IASLC) 2024 World Conference on Lung Cancer (WCLC 2024) in San Diego, California.

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that new data from the Phase 3 IMPALA-2 clinical trial of molgramostim in patients with autoimmune Pulmonary Alveolar Proteinosis (aPAP) were presented at the European Respiratory Society (ERS) Congress 2024 in Vienna, Austria. The poster from this presentation can be found here.

Qurate Retail, Inc. (“Qurate Retail”) (Nasdaq: QRTEA, QRTEB, QRTEP) announced that Greg Maffei, Executive Chairman of Qurate Retail, will be presenting at the Goldman Sachs Communacopia & Technology Conference on Tuesday, September 10th at 6:05 p.m. E.T. in San Francisco. During his presentation, Mr. Maffei may make observations regarding the company's financial performance and outlook, as well as other forward looking matters.

PORTLAND, Ore., Sept. 6, 2024 /PRNewswire/ -- Eastside Distilling, Inc. (Nasdaq: EAST) ("Eastside" or the "Company"), a consumer-focused beverage company that builds craft inspired experiential brands and high-quality artisan products around premium spirits, digital can printing, co-packing and mobile filling, announced today the closing of its previously announced registered direct offering for the sale and issuance of 442,042 shares of the Company's common stock (or pre-funded warrants in lieu thereof) to a single institutional investor at a purchase price of $1.00 per share or $0.9999 per pre-funded warrant.